• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Schizophrenia 
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for schizophrenia trials.

DOWNLOAD BROCHURE GET IN TOUCH

Effective solutions for advancing Schizophrenia research

Schizophrenia is a leading cause of patient suffering and disability around the world. Despite the compelling, unmet need for new and more effective treatments, the development process remains challenging. At Signant, we offer study sponsors a team with the scientific expertise and global experience, as well as innovative technology, to help run successful schizophrenia trials. Leverage our Signant SmartSignals suite to help your adult or pediatric trial succeed.

Schizophrenia-1

Why Signant Health

  • Monitor Study Data as They Flow In
  • Manage Rater Quality to Improve Data Reliability
  • Simplify Assessments and Adherence for Participants
  • Simplify Study Medication Management
  • Maximize Signal Detection Opportunities
  • Digitize Studies for End-to-end Accuracy and Visibility
  • Monitor Study Data as They Flow In

    Monitor Study Data as They Flow In

    By leveraging the most experience and largest data sets in Schizophrenia research, Signant's Blinded Data Analytics solution improves clinical data accuracy and reliability throughout the drug development cycle. Our clinical scientists and operations experts analyze study data at all relevant levels and make recommendations for appropriate interventions.

  • Manage Rater Quality to Improve Data Reliability

    Manage Rater Quality to Improve Data Reliability

    Our solutions provide site independent assessment of key eligibility criteria, ensuring that appropriate patients are enrolled, and that raters adhere to scoring and administrative conventions for efficacy outcomes.

  • Simplify Assessments and Adherence for Participants

    Simplify Assessments and Adherence for Participants

    Patient-reported and clinician-reported outcome assessments are vital to fully evaluate schizophrenia treatment efficacy and impact. Our eCOA solution can be tailored to sites' and patient's needs – guided assessments and built-in edit checks reduce COA errors, while alerts and reminders help improve adherence to medication dosing schedules.

  • Simplify Study Medication Management

    Simplify Study Medication Management

    Handle the medication management and patient randomization requirements in your protocol with ease. Our RTSM system and powerful algorithms handle complex dosing schedules, patient cohort schemes, and adaptive designs. Plus, our agile implementation model allows for rapid deployment including mid-study amendments.

  • Maximize Signal Detection Opportunities

    Maximize Signal Detection Opportunities

    Talk through your schizophrenia protocol with our science and medicine experts, who serve as an extension of your study team. We guide the selection and acquisition of endpoints and assessments, advise on inclusion/exclusion criteria, and recommend methods to decrease site and participant burdens. Our end goal is to optimize the reliability of your study's endpoint data.

  • Digitize Studies for End-to-end Accuracy and Visibility

    Digitize Studies for End-to-end Accuracy and Visibility

    While all of our solutions can be applied individually, when combined they enhance the data accuracy and operational efficiency of your schizophrenia study. Gain immediate access to electronic data to streamline and accelerate product approval.

Comprehensive Schizophrenia experience

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our Schizophrenia trial resources
SOLUTION BROCHURE

Schizophrenia Trial Solutions Overview


GET INSIGHTS
VIDEO

Schizophrenia Trial Solutions



WATCH [2 MIN]
CASE STUDY

Signant’s RTSM Manages Clinical IP Dispensation in Schizophrenia Study

 
READ CASE STUDY

eClinical solutions for Schizophrenia trials

Ready to learn more?

Discover how Signant can support your current or upcoming schizophrenia trials. 

DOWNLOAD BROCHURE GET STARTED